Related Experiment Video
Updated: May 5, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
Simvastatin-induced rhabdomyolysis
H McNaughton1, C J Mumford, C P Warlow
1Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK.
Simvastatin, a cholesterol-lowering statin drug, can cause acute rhabdomyolysis and kidney failure, even years after starting treatment. This case highlights the importance of monitoring for this rare but serious side effect.
Area of Science:
- Pharmacology
- Nephrology
- Hepatology
Background:
- Statins are widely prescribed for hyperlipidemia.
- Primary biliary cirrhosis is a chronic liver disease.
- Drug-induced toxicity requires careful consideration.
Purpose of the Study:
- To report a rare case of simvastatin-induced rhabdomyolysis.
- To discuss the differential diagnosis of muscle breakdown.
- To review the literature on statin-induced myopathy.
Main Methods:
- Case report presentation.
- Literature review on simvastatin toxicity.
- Analysis of clinical presentation and laboratory findings.
Main Results:
- A patient with primary biliary cirrhosis developed acute massive rhabdomyolysis and renal failure.
- The event occurred two years after initiating simvastatin therapy.
- The diagnosis was confirmed after excluding other causes.
Conclusions:
- Simvastatin can induce severe rhabdomyolysis and renal failure.
- Long-term use of statins may present risks.
- Vigilance for drug-induced myopathy is crucial in patients with underlying conditions.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Drug toxicity: Idiosyncratic Reactions
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Toxicity: Allergic Reactions
Drug Toxicity: Dose-Dependent Reactions

